Literature DB >> 3487305

Comparative oto-vestibular effects in the pigmented guinea pig after dibekacin and netilmicin treatment.

F Bamonte, G Melone, A Monopoli, E Ongini, A Forlani.   

Abstract

We treated groups of pigmented guinea pigs with either intramuscular netilmicin or dibekacin at 100 and 150 mg/kg per day for 3 weeks. Saline was used as the control solution. All animals were tested weekly for both vestibular and auditory functions. The vestibular function was evaluated by the duration of post-rotatory nystagmus (PRN) elicited by interrupting the rotation of the animal around the vertical axis; auditory function was evaluated by the threshold response for the Preyer's pinna reflex (PPR). All animals were then sacrificed and either their labyrinths or Corti organs were processed for further investigations using the scanning electron microscope (SEM). The duration of PRN decreased over the treatment period in all of the groups as a result of adaptation. However, 150 mg/kg dibekacin produced a significant decrease of the PRN responses as compared to the control and other groups. This effect also continued during the recovery period. Likewise, the PPR threshold of the animals receiving 150 mg/kg dibekacin showed a significant increase at the end of the treatments and during the recovery period, while the other dibekacin group had no significant auditory impairment. Netilmicin at both doses did not significantly affect responses following either vestibular or auditory stimulations. SEM observations demonstrated that the sensory epithelia of the labyrinths and Corti organs affected by 150 mg/kg dibekacin had great losses of stereocilia, while comparable doses of netilmicin (150 mg/kg) had only very moderate losses of stereocilia in the labyrinths but not in the Corti organs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3487305     DOI: 10.1007/BF00453764

Source DB:  PubMed          Journal:  Arch Otorhinolaryngol        ISSN: 0302-9530


  21 in total

1.  Comparative surface studies of ototoxic effects of various aminoglycoside antibiotics on the organ of Corti in the guinea pig. A scanning electron microscopic study.

Authors:  H M Theopold
Journal:  Acta Otolaryngol       Date:  1977 Jul-Aug       Impact factor: 1.494

2.  The nephrotoxicity of antimicrobial agents (second of three parts).

Authors:  G B Appel; H C Neu
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

3.  The comparative ototoxicities of gentamicin, tobramycin and dibekacin in the guinea pig. A functional and morphological cochlear and vestibular study.

Authors:  J M Aran; J P Erre; A Guilhaume; C Aurousseau
Journal:  Acta Otolaryngol Suppl       Date:  1982

4.  Comparative nephrotoxicities of gentamicin, netilmicin and tobramycin in the rat.

Authors:  L Soberon; R L Bowman; E Pastoriza-Munoz; G J Kaloyanides
Journal:  J Pharmacol Exp Ther       Date:  1979-09       Impact factor: 4.030

5.  The ototoxic potential of netilmicin compared with amikacin. An animal study in guinea pigs.

Authors:  J Wersäll
Journal:  Scand J Infect Dis Suppl       Date:  1980

6.  Inappropriate use of albino animals as models in research.

Authors:  D Creel
Journal:  Pharmacol Biochem Behav       Date:  1980-06       Impact factor: 3.533

7.  Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.

Authors:  C Cojocel; N Dociu; E Ceacmacudis; K Baumann
Journal:  Nephron       Date:  1984       Impact factor: 2.847

8.  Comparative nephrotoxicity of dibekacin and gentamicin in rats.

Authors:  W C Elliott; R A Parker; D C Houghton; D N Gilbert; W M Bennett
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-09

9.  Comparison of neuromuscular effects and acute toxicity of some aminoglycoside antibiotics.

Authors:  L Albiero; F Bamonte; E Ongini; L Parravicini
Journal:  Arch Int Pharmacodyn Ther       Date:  1978-06

10.  The nephrotoxic potential of netilmicin as determined in a rat model.

Authors:  F C Luft
Journal:  Scand J Infect Dis Suppl       Date:  1980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.